Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

0.2970
+0.01796.41%
Post-market: 0.29940.0024+0.81%19:17 EDT
Volume:122.79K
Turnover:35.45K
Market Cap:5.98M
PE:-0.16
High:0.2996
Open:0.2880
Low:0.2802
Close:0.2791
52wk High:5.12
52wk Low:0.2604
Shares:20.12M
Float Shares:17.66M
Volume Ratio:0.18
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8267
EPS(LYR):-2.0700
ROE:-8585.26%
ROA:-56.19%
PB:-1.21
PE(LYR):-0.14

Loading ...

Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep apnea, insomnia services venture

Reuters
·
Jun 10

Vivos Therapeutics Announces Key Collaboration Agreement With Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

THOMSON REUTERS
·
Jun 10

Vivos Therapeutics CEO to present at Small Cap Showcase & WTR Insights

Reuters
·
Jun 09

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

GlobeNewswire
·
Jun 09

Sector Update: Healthcare Stocks Higher Late Afternoon

MT Newswires Live
·
Jun 06

Vivos Therapeutics Agrees Debt for Equity Deal With Streeterville Capital

MT Newswires Live
·
Jun 05

Vivos Therapeutics agrees to exchange up to $4.5 million Streeterville debt into preferred, common stock

Reuters
·
Jun 05

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of up to $4.5 Million From Streeterville Capital to Support Continued Nasdaq Listing

THOMSON REUTERS
·
Jun 05

Press Release: Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Dow Jones
·
Jun 05

Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 04

Vivos Therapeutics Earnings Call: Growth Meets Cash Strain

TIPRANKS
·
May 22

Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)

TIPRANKS
·
May 21

Vivos Therapeutics Q1 revenue jumps, driven by SCN acquisition

Reuters
·
May 21

Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate

Benzinga Earnings
·
May 21

Vivos Therapeutics Q1 FY26 net loss more than doubles to $7.8 million; revenue rises 70% to $5.1 million

Reuters
·
May 21

BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million

Reuters
·
May 21

Vivos Therapeutics Q1 Gross Profit USD 3.059 Million

THOMSON REUTERS
·
May 21

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

THOMSON REUTERS
·
May 21

Vivos Therapeutics Delays Quarterly Filing

TIPRANKS
·
May 16

Vivos Therapeutics delays Q1 10-Q filing, seeks SEC extension

Reuters
·
May 16